{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:00:45Z","timestamp":1781712045463,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K07414"],"award-info":[{"award-number":["JP20K07414"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21K15368"],"award-info":[{"award-number":["JP21K15368"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21K15393"],"award-info":[{"award-number":["JP21K15393"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22H02841"],"award-info":[{"award-number":["JP22H02841"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23K15485"],"award-info":[{"award-number":["JP23K15485"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015644","name":"Pancreas Research Foundation of Japan","doi-asserted-by":"publisher","award":["Not available"],"award-info":[{"award-number":["Not available"]}],"id":[{"id":"10.13039\/100015644","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005928","name":"Daiwa Securities Health Foundation","doi-asserted-by":"publisher","award":["Not available"],"award-info":[{"award-number":["Not available"]}],"id":[{"id":"10.13039\/501100005928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","award":["Not available"],"award-info":[{"award-number":["Not available"]}],"id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012832","name":"Okinaka Memorial Institute for Medical Research","doi-asserted-by":"publisher","award":["Not available"],"award-info":[{"award-number":["Not available"]}],"id":[{"id":"10.13039\/100012832","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009665","name":"Vehicle Racing Commemorative Foundation","doi-asserted-by":"publisher","award":["Not available"],"award-info":[{"award-number":["Not available"]}],"id":[{"id":"10.13039\/100009665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21ck0106557"],"award-info":[{"award-number":["JP21ck0106557"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Few comprehensive studies have examined the associations of the ABO blood group with survival outcomes for patients with resected pancreatic cancer, overall and by adjuvant chemotherapy regimens.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This multicenter study enrolled 1153 patients with resected pancreatic cancer. The hazard ratios (HRs) for disease-free and pancreatic cancer-specific survival were calculated with adjustment for potential confounders, including <jats:italic>KRAS<\/jats:italic> mutation and CDKN2A (p16), TP53, and SMAD4 expression, using the Cox proportional hazards regression model. Blood group antigen expression in tumors was immunohistochemically assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The ABO blood group was not associated with disease-free or pancreatic cancer-specific survival (<jats:italic>P<\/jats:italic> &gt; 0.90). For pancreatic cancer-specific survival, blood groups A, B, and AB had multivariable HRs of 0.97 (95% confidence interval [CI], 0.81\u20131.15), 1.03 (95% CI, 0.83\u20131.26), and 0.99 (95% CI, 0.76\u20131.30), respectively (vs. O). The associations between ABO blood group and disease-free and pancreatic cancer-specific survival differed according to the adjuvant chemotherapy regimens (<jats:italic>P<\/jats:italic>\n              <jats:sub>interaction<\/jats:sub> = 0.011 and 0.008, respectively). For the patients without chemotherapy, the HRs for disease-free survival were 0.99 (95% CI, 0.69\u20131.41) for blood group A, 1.65 (95% CI, 1.09\u20132.48) for blood group B, and 1.79 (95% CI, 1.01\u20133.17) for blood group AB, (vs. O). For the patients receiving S-1-based chemotherapy, blood group AB (vs. O) exhibited a reverse association (HR, 0.63; 95% CI, 0.39\u20131.00). Similar interactions were observed when blood group antigen expression in tumors was analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The ABO blood group is not a prognostic biomarker in resected pancreatic cancer overall but may predict the effectiveness of adjuvant chemotherapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1245\/s10434-025-17289-7","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T09:41:29Z","timestamp":1746178889000},"page":"6477-6491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overall and by Adjuvant Chemotherapy Regimens"],"prefix":"10.1245","volume":"32","author":[{"given":"Yosuke","family":"Inoue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Masugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3937-2755","authenticated-orcid":false,"given":"Tsuyoshi","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikuni","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousuke","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sasahira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Uematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Ushiku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Fujishiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Kitago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the GTK Pancreatic Cancer Study Group in Japan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyoshi","family":"Iwakoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kikuko","family":"Kaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"17289_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin."},{"key":"17289_CR2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/jhbp.844","volume":"28","author":"Y Inoue","year":"2021","unstructured":"Inoue Y, Saiura A, Oba A, et al. Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: intention-to-treat analysis compared with upfront surgery. J Hepatobiliary Pancreat Sci. 2021;28:143\u201355.","journal-title":"J Hepatobiliary Pancreat Sci."},{"key":"17289_CR3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet London England. 2016;388:248\u201357.","journal-title":"Lancet London England."},{"key":"17289_CR4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/SLA.0000000000003284","volume":"273","author":"MJ Truty","year":"2021","unstructured":"Truty MJ, Kendrick ML, Nagorney DM, et al. Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline\/locally advanced pancreatic cancer. Ann Surg. 2021;273:341\u20139.","journal-title":"Ann Surg."},{"key":"17289_CR5","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1245\/s10434-014-3842-z","volume":"21","author":"BA Boone","year":"2014","unstructured":"Boone BA, Steve J, Zenati MS, et al. Serum CA 19\u20139 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann Surg Oncol. 2014;21:4351\u20138.","journal-title":"Ann Surg Oncol."},{"key":"17289_CR6","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1245\/s10434-012-2809-1","volume":"20","author":"W Hartwig","year":"2013","unstructured":"Hartwig W, Strobel O, Hinz U, et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol. 2013;20:2188\u201396.","journal-title":"Ann Surg Oncol."},{"key":"17289_CR7","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/MPA.0b013e3182056b1c","volume":"40","author":"S Satoi","year":"2011","unstructured":"Satoi S, Yanagimoto H, Toyokawa H, et al. Selective use of staging laparoscopy based on carbohydrate antigen 19\u20139 level and tumor size in patients with radiographically defined potentially or borderline resectable pancreatic cancer. Pancreas. 2011;40:426\u201332.","journal-title":"Pancreas."},{"key":"17289_CR8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pan.2020.11.026","volume":"21","author":"Y Ushida","year":"2021","unstructured":"Ushida Y, Inoue Y, Ito H, et al. High CA19-9 level in resectable pancreatic cancer is a potential indication of neoadjuvant treatment. Pancreatology. 2021;21:130\u20137.","journal-title":"Pancreatology."},{"key":"17289_CR9","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.pan.2018.08.003","volume":"18","author":"G Luo","year":"2018","unstructured":"Luo G, Fan Z, Cheng H, et al. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer. Pancreatology. 2018;18:971\u20136.","journal-title":"Pancreatology."},{"key":"17289_CR10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.amjsurg.2008.12.031","volume":"198","author":"D Marrelli","year":"2009","unstructured":"Marrelli D, Caruso S, Pedrazzani C, et al. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg. 2009;198:333\u20139.","journal-title":"Am J Surg."},{"key":"17289_CR11","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/ng.429","volume":"41","author":"L Amundadottir","year":"2009","unstructured":"Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet. 2009;41:986\u201390.","journal-title":"Nat Genet."},{"key":"17289_CR12","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/1055-9965.EPI-20-1581","volume":"30","author":"T Hamada","year":"2021","unstructured":"Hamada T, Oyama H, Nakai Y, et al. ABO blood group and risk of pancreatic carcinogenesis in intraductal papillary mucinous neoplasms. Cancer Epidemiol Biomarkers Prev. 2021;30:1020\u20138.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"17289_CR13","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/j.1349-7006.2011.01907.x","volume":"102","author":"M Nakao","year":"2011","unstructured":"Nakao M, Matsuo K, Hosono S, et al. ABO blood group alleles and the risk of pancreatic cancer in a Japanese population. Cancer Sci. 2011;102:1076\u201380.","journal-title":"Cancer Sci."},{"key":"17289_CR14","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1093\/aje\/kws458","volume":"177","author":"HA Risch","year":"2013","unstructured":"Risch HA, Lu L, Wang J, et al. ABO blood group and risk of pancreatic cancer: a study in Shanghai and meta-analysis. Am J Epidemiol. 2013;177:1326\u201337.","journal-title":"Am J Epidemiol."},{"key":"17289_CR15","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/jnci\/djp020","volume":"101","author":"BM Wolpin","year":"2009","unstructured":"Wolpin BM, Chan AT, Hartge P, et al. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst. 2009;101:424\u201331.","journal-title":"J Natl Cancer Inst."},{"key":"17289_CR16","first-page":"5422","volume":"48","author":"PM Pour","year":"1988","unstructured":"Pour PM, Tempero MM, Takasaki H, et al. Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19\u20139 in pancreatic cancer cells in comparison with the patient\u2019s blood group type. Cancer Res. 1988;48:5422\u20136.","journal-title":"Cancer Res."},{"key":"17289_CR17","doi-asserted-by":"crossref","first-page":"Fso107","DOI":"10.4155\/fsoa-2015-0012","volume":"2","author":"SK Rummel","year":"2016","unstructured":"Rummel SK, Ellsworth RE. The role of the histoblood ABO group in cancer. Future Sci OA. 2016;2:Fso107.","journal-title":"Future Sci OA."},{"key":"17289_CR18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000345028","volume":"84","author":"A Handra-Luca","year":"2013","unstructured":"Handra-Luca A. A and B blood group antigens in human pancreatic ductal adenocarcinomas. Oncology. 2013;84:141\u20139.","journal-title":"Oncology."},{"key":"17289_CR19","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.hpb.2020.01.004","volume":"22","author":"H Williams","year":"2020","unstructured":"Williams H, Jajja MR, Hashmi SS, et al. Association of ABO blood group with survival following pancreatoduodenectomy for pancreatic ductal adenocarcinoma. HPB. 2020;22:1557\u201362.","journal-title":"HPB."},{"key":"17289_CR20","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.hpb.2018.03.009","volume":"20","author":"K Khalil","year":"2018","unstructured":"Khalil K, Bansal S, Ayaani S, et al. Does blood group affect survival following pancreatoduodenectomy for periampullary malignancy? HPB. 2018;20:848\u201353.","journal-title":"HPB."},{"key":"17289_CR21","doi-asserted-by":"crossref","first-page":"e41984","DOI":"10.1371\/journal.pone.0041984","volume":"7","author":"DS Wang","year":"2012","unstructured":"Wang DS, Wang ZQ, Zhang L, et al. Are risk factors associated with outcomes in pancreatic cancer? PloS One. 2012;7:e41984.","journal-title":"PloS One."},{"key":"17289_CR22","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/jhbp.1152","volume":"29","author":"K Tezuka","year":"2022","unstructured":"Tezuka K, Ohgi K, Okamura Y, et al. The prognostic impact of ABO blood type in pancreatic cancer: relevance to adjuvant chemotherapy. J Hepato-Biliary-Pancreatic Sci. 2022;29:922\u201331.","journal-title":"J Hepato-Biliary-Pancreatic Sci."},{"key":"17289_CR23","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1002\/cam4.5476","volume":"12","author":"C Wang","year":"2023","unstructured":"Wang C, Zhou J, Wang L, et al. ABO blood groups and expression of blood group antigens of epithelial ovarian cancer in Chinese women. Cancer Med. 2023;12:7498\u2013507.","journal-title":"Cancer Med."},{"key":"17289_CR24","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199104183241603","volume":"324","author":"JS Lee","year":"1991","unstructured":"Lee JS, Ro JY, Sahin AA, et al. Expression of blood-group antigen A: a favorable prognostic factor in non-small-cell lung cancer. N Engl J Med. 1991;324:1084\u201390.","journal-title":"N Engl J Med."},{"key":"17289_CR25","first-page":"3014","volume":"45","author":"JS Coon","year":"1985","unstructured":"Coon JS, Watkins JR, Pauli BU, Weinstein RS. Flow cytometric analysis of heterogeneity in blood group-related antigen expression in a human urinary bladder carcinoma cell line, 647V. Cancer Res. 1985;45:3014\u201321.","journal-title":"Cancer Res."},{"key":"17289_CR26","first-page":"1560","volume":"45","author":"B Drewinko","year":"1985","unstructured":"Drewinko B, Lichtiger B. Full expression of blood group-related, transplantation-related, and carcinoembryonic antigens in human colorectal cancer cells with different degrees of phenotypic differentiation. Cancer Res. 1985;45:1560\u20134.","journal-title":"Cancer Res."},{"key":"17289_CR27","first-page":"425","volume":"79","author":"SH Itzkowitz","year":"1987","unstructured":"Itzkowitz SH, Yuan M, Ferrell LD, et al. Cancer-associated alterations of blood group antigen expression in the human pancreas. J Natl Cancer Inst. 1987;79:425\u201334.","journal-title":"J Natl Cancer Inst."},{"key":"17289_CR28","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1002\/1097-0142(19910615)67:12<3042::AID-CNCR2820671219>3.0.CO;2-L","volume":"67","author":"K Tauchi","year":"1991","unstructured":"Tauchi K, Kakudo K, Machimura T, Makuuchi H, Mitomi T. Immunohistochemical studies of blood group-related antigens in human superficial esophageal carcinomas. Cancer. 1991;67:3042\u201350.","journal-title":"Cancer."},{"key":"17289_CR29","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1111\/cas.15398","volume":"113","author":"T Suzuki","year":"2022","unstructured":"Suzuki T, Masugi Y, Inoue Y, et al. KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. Cancer Sci. 2022;113:3097\u2013109.","journal-title":"Cancer Sci."},{"key":"17289_CR30","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/cjp2.323","volume":"9","author":"Y Masugi","year":"2023","unstructured":"Masugi Y, Takamatsu M, Tanaka M, et al. Postoperative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression. J Pathol Clin Res. 2023;9:339\u201353.","journal-title":"J Pathol Clin Res."},{"key":"17289_CR31","unstructured":"Japan Pancreas Society. Classification of Pancreatic Carcinoma. 4th English ed; Kanehara, Tokyo, Japan; 2017."},{"key":"17289_CR32","volume-title":"TNM classification of malignant tumours","author":"JD Brierley","year":"2017","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 8th edn. Oxford: Wiley-Blackwell; 2017.","edition":"8"},{"key":"17289_CR33","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.6004\/jnccn.2017.0131","volume":"15","author":"MA Tempero","year":"2017","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2017;15:1028\u201361.","journal-title":"J Natl Compr Cancer Netw."},{"key":"17289_CR34","volume-title":"Digestive system tumours: WHO classification of tumours","author":"The WHO Classification of Tumours Editorial Board","year":"2019","unstructured":"The WHO Classification of Tumours Editorial Board. Digestive system tumours: WHO classification of tumours. 5th edn. Geneva: World Health Organization; 2019.","edition":"5"},{"key":"17289_CR35","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1200\/JCO.2016.70.7547","volume":"35","author":"T Hamada","year":"2017","unstructured":"Hamada T, Cao Y, Qian ZR, et al. Aspirin use and colorectal cancer survival according to tumor CD274 (programmed cell death 1 ligand 1) expression status. J Clin Oncol. 2017;35:1836\u201344.","journal-title":"J Clin Oncol."},{"key":"17289_CR36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","volume":"10","author":"WG Cochran","year":"1954","unstructured":"Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101\u201329.","journal-title":"Biometrics."},{"key":"17289_CR37","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jnci\/djp447","volume":"102","author":"M Dandona","year":"2010","unstructured":"Dandona M, Gao F, Linehan DC, Wang-Gillam A. Re: ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst. 2010;102:135\u20137.","journal-title":"J Natl Cancer Inst."},{"key":"17289_CR38","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/cam4.1097","volume":"6","author":"K El Jellas","year":"2017","unstructured":"El Jellas K, Hoem D, Hagen KG, et al. Associations between ABO blood groups and pancreatic ductal adenocarcinoma: influence on resection status and survival. Cancer Med. 2017;6:1531\u201340.","journal-title":"Cancer Med."},{"key":"17289_CR39","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/1471-2407-12-319","volume":"12","author":"NN Rahbari","year":"2012","unstructured":"Rahbari NN, Bork U, Hinz U, et al. AB0 blood group and prognosis in patients with pancreatic cancer. BMC Cancer. 2012;12:319.","journal-title":"BMC Cancer."},{"key":"17289_CR40","first-page":"451","volume":"117","author":"C Ernst","year":"1984","unstructured":"Ernst C, Thurin J, Atkinson B, et al. Monoclonal antibody localization of A and B isoantigens in normal and malignant fixed human tissues. Am J Pathol. 1984;117:451\u201361.","journal-title":"Am J Pathol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17289-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17289-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17289-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:01:05Z","timestamp":1754150465000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17289-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["17289"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17289-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"6 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Drs. Masugi and Hamada acknowledge research funding from the Daiichi Sankyo TaNeDS Funding Program. Dr. Sasahira acknowledges scholarship donation to institution and honararia for speakers from Taiho Pharmaceutical. Dr. Takeuchi acknowledges consultancy fees from Nichirei Bioscience, Nippon Shinyaku, and Meiji Seika Pharma; research support from Fujirebio, SONY, and Daiichi Sankyo; honoraria from Eli Lilly, Chugai, Kyowa Kirin, and Janssen; and royalties from Sysmex, AMOY, and Nichirei bioscience. This work was not funded by any of those companies. No other conflicts of interest exist.\u00a0The remaining authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}